Lower dose EURneffy® nasal adrenaline spray approved by MHRA for younger children

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a lower-dose version of the adrenaline nasal spray, EURneffy®, for the emergency treatment of serious allergic reactions (anaphylaxis) in children aged four years and over. This adrenaline device option is expected to become available on prescription towards the end of 2026, giving children at risk of life-threatening allergies a new way to carry life-saving medication.

What is EURneffy®?

EURneffy® is the first adrenaline nasal spray approved in the UK to treat anaphylaxis, a serious allergic reaction that can occur within minutes of exposure to allergens such as foods, insect stings, or medications. Anaphylaxis causes life-threatening symptoms like breathing difficulties, swelling of the airways, and dangerously low blood pressure, all of which require immediate treatment with adrenaline.

Until recently, the only way patients could self-administer adrenaline during anaphylaxis has been with adrenaline auto-injectors (AAIs) — portable devices that inject the medicine into the thigh using a needle.

The newly approved 1 mg dose nasal spray is indicated for children aged four years and over weighing between 15 kg and 30 kg. This extends access beyond the previously authorised 2 mg product, which is intended for adults and children who weigh 30 kg or more.

How does EURneffy® work?

Each EURneffy® device contains one ready-to-use 1 mg dose of adrenaline, and works as follows:

1.Insert the tip into one nostril.

2.Press the plunger to release the full dose of adrenaline.

The medicine is absorbed through the lining of the nose and quickly enters the bloodstream—even if the nose is blocked by a cold or allergy. Once absorbed, adrenaline:

• Narrows blood vessels to raise low blood pressure
• Relaxes airway muscles to ease breathing
• Reduces swelling and hives caused by the allergic reaction

As with AAIs, patients should always carry two devices in case a second dose is needed. Training and a clear Patient Information Leaflet will be provided with any prescription.

Why is this approval important?

Prompt administration of adrenaline is critical in treating anaphylaxis. However, some individuals delay or avoid using auto-injectors due to fear of needles, uncertainty about how to use them, or concerns about needing hospital treatment afterwards.

EURneffy® offers a needle-free alternative, which may help reduce hesitation and support faster treatment during emergencies. Its compact design may also make it easier to carry, encouraging people to have their medication readily available at all times.

By addressing both psychological and practical barriers, EURneffy® could help more individuals access timely adrenaline treatment in an emergency.

What does this mean for people with allergies?

EURneffy®  (1mg) is expected to become available in the UK from late 2026. How quickly people can access it will depend on final regulatory steps, arrangements for pricing and supply, and readiness among healthcare professionals. It won’t be available straight away, and children who currently use AAIs will not be automatically switched. Instead, once EURneffy® is available, healthcare professionals will work with each patient and parent / carer to decide whether a nasal spray, an injector, or both are most appropriate.

Staying prepared

People at risk of anaphylaxis should:

• Always carry two prescribed adrenaline devices.  Learn more about care and medication in our Guide.
• Ensure family members, friends, or caregivers know how to respond in an emergency.
• Familiarise yourself with the instructions for your device (EpiPen, Jext, or Eurneffy®).
• Report any concerns or side effects to a GP, pharmacist, or via the MHRA Yellow Card scheme.

Read the MHRA press release here.

For any questions, please contact our helpline by email at info@anaphylaxis.org.uk or by telephone on 01252 542029.